BioInvent to Present Clinical Data from its Two Leading Assets at ASCO 2024 [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
combination data from the Phase 1/2a study with BI-1206 in combination with KEYTRUDA for the treatment of patients with solid tumors Both BI-1808 and BI-1206 are first-in-class immunomodulatory agents with the potential to improve the efficacy of immune therapies and improve cancer outcomes BI-1808, an anti-TNFR2 antibody capable of targeting Tregs and modifying the tumor microenvironment, that could represent a new class of checkpoint inhibitors BI-1206, which blocks FcyRIIB, could overcome resistance to PD-1 inhibition Both posters will be presented at the American Society for Clinical Oncology (ASCO 2024) Annual Meeting taking place at the McCormick Place Convention Center in Chicago, Illinois from May 31st to June 4th LUND, SWEDEN / ACCESSWIRE / April 24, 2024 / BioInvent International AB ("BioInvent") (STO:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Here's Why Merck (MRK) is a Strong Momentum Stock [Yahoo! Finance]Yahoo! Finance
- Generic Sterile Injectable Market Size to Worth USD 108.54 Bn by 2033 [Yahoo! Finance]Yahoo! Finance
- 4M Therapeutics Announces Formation of Clinical Advisory Board with Experts in Neuropsychiatry and Neurodegeneration [Yahoo! Finance]Yahoo! Finance
- Merck reports data from Phase III gastric cancer treatment trial [Yahoo! Finance]Yahoo! Finance
- The top pharmaceutical companies by R&D expenditure [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 4/25/24 - Beat
MRK
Sec Filings
- 5/3/24 - Form 10-Q
- 5/2/24 - Form 4
- 5/2/24 - Form 4
- MRK's page on the SEC website